Back to Results
First PageMeta Content
Bristol-Myers Squibb / Cetuximab / Bevacizumab / FOLFIRI / KRAS / Colorectal cancer / Panitumumab / Cancer and Leukemia Group B / FOLFOX / Medicine / Chemotherapy regimens / Cancer organizations


Overall survival in all RAS wild type patients in CALGB/SWOGstudy
Add to Reading List

Document Date: 2015-03-16 01:05:14

Open Document

File Size: 1,01 MB

Share Result on Facebook

Company

Merck Serono Pty Ltd. / Leukemia Group B/Southwest Oncology Group / PBAC / ITT / /

Country

Australia / Germany / /

Currency

CRC / /

Event

FDA Phase / Man-Made Disaster / /

Facility

Consumer Comments facility / Public hospital / Private Hospital / /

IndustryTerm

treatment of metastatic colorectal cancer / treatment for patients with metastatic colorectal cancer / cancer Treatment / treatment for patient with metastatic colorectal cancer / /

MedicalCondition

common cancer / rat sarcoma / metastatic colorectal cancer-subgroup analysis / cancer / disease / KRAS WT tumours / RAS WT tumours / colorectal cancer PBS / tumour / metastatic colorectal cancer / sarcoma / untreated advanced colorectal adenocarcinoma / Bowel cancer / Clin Colorectal Cancer / treatment colorectal cancer / untreated metastatic adenocarcinoma / KRAS wild-type metastatic colorectal cancer / KRAS-mutated tumours / KRASmutated tumours / tumours / /

MedicalTreatment

chemotherapy / /

Organization

OR RD / Congress / World Health Organization / Private Hospital / European Medicines Agency / Public hospital / European Society for Medical Oncology / TGA / European Society of Medical Oncology / /

/

Position

editor / Dental Medical Practitioners Nurse / representative / *Investigator / Private / /

Product

Qty form CETUXIMAB Injection / CETUXIMAB Injection / fluorouracil / Erbitux / Chemotherapy / FIRE-3 / FOLFIRI / cetuximab / /

PublishedMedium

Journal of Clinical Oncology / /

Technology

RAS WT mCRC Trial ID Protocol / antibodies / chemotherapy / /

URL

http /

SocialTag